ReviewDrugs2019
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature.Nutrients · 2021Pooled it
- Nomogram Analysis for Predicting Response to Androgen-Receptor-Axis-Targeted Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer.Cancer medicine · 2024Article
- Recent advances in flavonoid compounds for the treatment of prostate cancer.Molecular biology reports · 2024Review
- Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.Cancer medicine · 2023Article
- Aberrant expression of multiple glycolytic enzyme genes is significantly associated with disease progression and survival outcomes in prostate cancers.American journal of clinical and experimental urology · 2023Article
- Jumonji domain-containing protein RIOX2 is overexpressed and associated with worse survival outcomes in prostate cancers.Frontiers in oncology · 2023Article
- Translational Bioinformatics for Human Reproductive Biology Research: Examples, Opportunities and Challenges for a Future Reproductive Medicine.International journal of molecular sciences · 2022Review
- Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy.Future science OA · 2022Article
- Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective.Frontiers in oncology · 2022Review
- Evaluation ofReports of biochemistry & molecular biology · 2021Article
- Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer.Hormones (Athens, Greece) · 2021Review
- Urologic malignancies: advances in the analysis and interpretation of clinical findings.Future science OA · 2021Article
- The Contribution of Clinical Pharmacologists in Precision Medicine: An Opportunity for Health Care Improvement.Current therapeutic research, clinical and experimental · 2021Review
- Prostate Microbiota and Prostate Cancer: A New Trend in Treatment.Frontiers in oncology · 2021Review
- Targeting DNA Damage Response in Prostate and Breast Cancer.International journal of molecular sciences · 2020Review
- Depression and prostate cancer: implications for urologists and oncologists.Nature reviews. Urology · 2020Review
- Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.Molecular oncology · 2020Article
- Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity.Cancer cell international · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PC) is a major health issue in developed countries, with, on the one hand, men suffering from sequelae related to unnecessary treatment of non-lethal PC, and, on the other hand, still dying because of advanced PC that progresses to castration-resistant disease. Systemic treatment is the mainstay of therapy of castration-resistant PC (CRPC). To date, a multitude of systemic agents have been tested and many of these have failed to provide a clinically meaningful benefit in CRPC, while others have been approved by the US Food and Drug Administration and/or the European Medicines Agency, including antiandrogen hormonal drugs (abiraterone, enzalutamide, apalutamide), chemotherapy (docetaxel and cabazitaxel), immunotherapy (Sipuleucel-T), and radiopharmaceutical (Radium-223) agents. In this review, systemic treatments regarded as most likely to have an impact in clinical practice are presented and discussed. In addition to the pivotal clinical studies, selected retrospective and non-randomized clinical trials are also discussed if deemed to have an impact on clinical practice or future research. A comprehensive appraisal of the expanding landscape of systemic therapies for advanced PC is provided from an expert perspective, with a focus on novel classification and diagnostic tools that have been paving the way for the development of precision medicine in PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.